Seroconversion of hepatitis B vaccine in infants related to the mother's serostatus in a community of São José dos Campos, state of São Paulo, Brazil

Clinics

Volumn 61, Issue 5, 2006, Pages 387-394

  Ribeiro, Tereza Monteiro ^a   Azevedo, Raymundo Soares ^a  

^a Basic Health Unit of Campo Dos Alemães   (Brazil)

Author keywords

Antibody waning; Hepatitis B; Seroconversion; Seroprevalence; Vaccination

Indexed keywords

EID: 33750384451     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322006000500004     Document Type: Article

References (16)

1. Assad S, Francis A. Over a decade of experience with a yeast recombinant hepatitis B vaccine. Vaccine. 2000;18:57-67.
2. Chauvin P, Ekra D, Plotkin SA. The cost of not implementing routine neonates immunization programmes in HBsAg high prevalence countries. Vaccine. 2002;20:2848-50.
3. rd ed. Philadelphia: Saunders; 1999.
4. Pendelenton E. Infection control screen saver. Nurs Times. 1997;93:65-8.
5. Poovorawan Y, Theamboonlers A, Vimolket T, Sinlaparatsamee S, Chaiear K, Siraprapasiri T, et al. Impact of hepatitis B immunisation as part of the EPI. Vaccine. 2000;19:943-9.
6. Centers for Disease Control. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal child vaccination. Recommendations of the Immunization Practices Advisory Committee. MMWR. 1991;40:1-25.
7. Erdem M, Sahin I, Erdem A, Gursoy R, Yildiz A, Guner H. Prevalence of hepatitis B surface antigen among pregnant women in a low-risk population. Int J Gynecol Obstet. 1994;44:125-8.
8. Chunsuttiwat S, Biggs BA, Maynard J, Thamapalo S, Laoboripat S, Bovornsin S, et al. Integration of hepatitis B vaccination into the expanded programme on immunization in Chonburi and Chiangmai provinces, Thailand. Vaccine. 1997;15:769-74.
9. El Khouri M, Duarte LS, Ribeiro RB, Silva LF, Camargo LM, Santos VA, et al. Seroprevalence of hepatitis B virus and hepatitis C virus in Monte Negro in the Brazilian western Amazon region. Clinics. 2005;60:29-36.
10. Shokri F, Amani A. High rate of seroconversion following administration of a single supplementary dose of a recombinant hepatitis B vaccine in Iranian healthy nonresponse neonates. Med Microbiol Immunol. 1997;185:231.
11. rd edition. Oxford: Blackwell Science; 1998.
12. Liao SS, Li RC, Li H, Yang JY, Zeng XJ, Gong J, et al. Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children. Vaccine. 1999;17:2661-6.
13. th, 2006.
14. th 2006.
15. Fortuin M, Chotard J, Jack AD, Maine NP, Mendy M, Hall AJ, et al. Efficacy of hepatitis B vaccine in the Gambian expanded programme of immunisation. The Lancet. 1993;341:1129-31.
16. Motta MSF, Mussi-Pinhata MM, Jorge SM, Yoshida CFT, Souza CBS. Immunogenicity of hepatitis B vaccine in preterm and full term infants vaccinated within the first week of life. Vaccine. 2002;20:1557-62.